Bleb Vascularity Change After Subconjunctival Injection Bevacizumab

Phase 4

• Conditions: Bleb Vascularity; Conjunctival Scarring

• Registration Number: NCT00815594
• Lead Sponsor: Capital Medical University

Brief Summary

The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2008-12
• Study Start: 2008-12
• Study First Submitted: 2008-12-29
• Study First Submitted QC: 2008-12-29
• Last Update Submitted: 2008-12-29
• Study First Posted: 2008-12-30
• Last Update Posted: 2008-12-30
• Primary Completion: 2009-03
• Study Completion: 2009-05

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Glaucoma patients after trabeculectomy whose bleb is hyperaemia

Read More

Exclusion Criteria

• Affected eye has normal IOP
• Not allergic with Avastin

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
bleb vascular change	one day, one week, one month

Trial Locations

Locations (1)

Tongren hospital; 🇨🇳 Beijing, Beijing, China